Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
|
| Abstract |
The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.
|
|---|---|
| Authors | Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo, Takashi Nakakuma, Hirofumi Yamada, Kei Kimizuka, Tohru Higuchi, SBCCSG-36 investigators |
| Journal | Investigational new drugs (Invest New Drugs) Vol. 37 Issue 3 Pg. 592-593 (Jun 2019) ISSN: 1573-0646 [Electronic] United States |
| PMID | 31025237 (Publication Type: Published Erratum) |
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!